JP2001522857A5 - - Google Patents

Download PDF

Info

Publication number
JP2001522857A5
JP2001522857A5 JP2000520457A JP2000520457A JP2001522857A5 JP 2001522857 A5 JP2001522857 A5 JP 2001522857A5 JP 2000520457 A JP2000520457 A JP 2000520457A JP 2000520457 A JP2000520457 A JP 2000520457A JP 2001522857 A5 JP2001522857 A5 JP 2001522857A5
Authority
JP
Japan
Prior art keywords
minutes
eluent
mixture
column
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000520457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001522857A (ja
Filing date
Publication date
Priority claimed from GBGB9723589.9A external-priority patent/GB9723589D0/en
Application filed filed Critical
Publication of JP2001522857A publication Critical patent/JP2001522857A/ja
Publication of JP2001522857A5 publication Critical patent/JP2001522857A5/ja
Pending legal-status Critical Current

Links

JP2000520457A 1997-11-08 1998-11-06 化合物 Pending JP2001522857A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds
GB9723589.9 1997-11-08
PCT/EP1998/007021 WO1999024449A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (2)

Publication Number Publication Date
JP2001522857A JP2001522857A (ja) 2001-11-20
JP2001522857A5 true JP2001522857A5 (enExample) 2006-01-05

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000520457A Pending JP2001522857A (ja) 1997-11-08 1998-11-06 化合物

Country Status (29)

Country Link
US (1) US6455510B1 (enExample)
EP (2) EP1030857B1 (enExample)
JP (1) JP2001522857A (enExample)
KR (1) KR20010031875A (enExample)
CN (1) CN1285843A (enExample)
AP (1) AP2000001801A0 (enExample)
AR (1) AR011229A1 (enExample)
AT (1) ATE273990T1 (enExample)
AU (1) AU2048399A (enExample)
BR (1) BR9813976A (enExample)
CA (1) CA2309200A1 (enExample)
CO (1) CO5021135A1 (enExample)
DE (1) DE69825780T2 (enExample)
EA (1) EA200000392A1 (enExample)
EE (1) EE200000285A (enExample)
ES (1) ES2222621T3 (enExample)
GB (1) GB9723589D0 (enExample)
HR (1) HRP20000275A2 (enExample)
HU (1) HUP0004082A2 (enExample)
IL (1) IL135964A0 (enExample)
IS (1) IS5477A (enExample)
MA (1) MA26565A1 (enExample)
NO (1) NO20002361L (enExample)
PE (1) PE20000013A1 (enExample)
PL (1) PL340921A1 (enExample)
SK (1) SK6722000A3 (enExample)
TR (1) TR200002131T2 (enExample)
WO (1) WO1999024449A2 (enExample)
ZA (1) ZA9810125B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
AU2002362443B2 (en) 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
AU2003263846B2 (en) * 2002-08-15 2009-12-17 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
KR20070050484A (ko) * 2004-09-09 2007-05-15 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 A1 및 a3 아데노신 수용체 아고니스트로서의 퓨린 유도체
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
IN2012DN01453A (enExample) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University COMBINATION THERAPY FOR A PI3K-ASSOCIATED DISEASE OR DISORDER
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Similar Documents

Publication Publication Date Title
JP2001522858A5 (enExample)
KR900008743B1 (ko) 안트라시클리논 글리코시드의 정제방법
Adam et al. Routine synthesis of L-[18F] 6-fluorodopa with fluorine-18 acetyl hypofluorite
RU2001118849A (ru) Очистка циклопептидных соединений эхинокандина
FR2581647A1 (fr) Procede de purification de l'insuline
JP2003534349A (ja) (ss,rs)−s−アデノシル−l−メチオニンの薬剤として許容される塩の調製方法
Lin et al. Evaluation of new chiral stationary phases of bonded cyanuric chloride with amino acid and naphthylalkylamine substituents for liquid chromatographic separation of amino acids and amino alcohols as dinitrobenzoyl derivatives
JPH07278081A (ja) ヨウ素化造影剤の製造方法
JPS63218857A (ja) 液体クロマトグラフイ−用充てん剤
Volland et al. Stereoselective analysis of fenoprofen and its metabolites
CN113061152A (zh) 一种利用氨基型树脂分离纯化甘油葡萄糖苷的方法
JP3141029B2 (ja) ペントスタチンの精製方法
JP2001026567A (ja) シキミ酸の精製方法
WO2001030796A1 (en) A process for preparing acarbose with high purity
CN104148037A (zh) 一种精氨酸键合型亲水色谱固定相及制备方法
CN119613391B (zh) 一种恩格列净的纯化方法
Ashton HPLC determination of chloramphenicol, chloramphenicol monosuccinate and chloramphenicol glucuronide in biological matrices
JP2002504855A (ja) グラディエント溶離法
MIYASHITA et al. Studies on Iodinated Compounds. I. Improved Procedure for Preparation of Monoiodohistidine
JP4070904B2 (ja) イオン化する化合物用の分離剤およびその製造方法
ARAKAWA et al. Improved Synthesis of Sulfoconjugate Isomers of Norepinephrine and Epinephrine, and Separation of All Sulfoconjugates of Catecholamines by Thin-Layer and High-Performance Liquid Chromatography
Tang et al. A method for the selective release and, hence, assay of the carbohydrate moieties of collagen
JPS6256491A (ja) 高純度メチルコバラミンの製造法
Vaccher et al. GABA-B agonists: enantiomeric resolution of 4-amino-3-(5-chlorothien-2-yl) butyric acid and analogues on chiral crown ether stationary phase
JPH01190695A (ja) グリチルリチンの精製法